Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 65, Issue 11, Pages 7786-7798Publisher
AMER CHEMICAL SOC
DOI: 10.1021/acs.jmedchem.2c00141
Keywords
-
Categories
Funding
- National Natural Science Foundation of China [21877059, 91953201, 92153303]
Ask authors/readers for more resources
PtPAN is a platinum-based photosensitizer that is unreactive to DNA in the dark but highly cytotoxic upon near-infrared irradiation for oxygen-independent photodynamic therapy. With its two-photon excitation property, PtPAN may be suitable for the treatment of deep solid tumors.
Platinum-based photosensitizers are promising anticancer agents in photodynamic therapy. The cytotoxic effects primarily arise from the production of singlet oxygen and platination of DNA. However, their efficacy is limited by drug resistance and hypoxic tumor microenvironment. A naphthalimidemodified cyclometalated platinum(II) complex PtPAN [PA = N(2-(diethylamino)ethyl)picolinamide, N = N-(2'-ethylhexyl)-4-ethynyl-1,8-naphthalimide] is designed to conquer these problems. PtPAN generates ROS efficiently under both normoxia and hypoxia. It does not interact with DNA and shows low cytotoxicity in the dark, while it kills tumor cells via ROS under near-infrared light irradiation; moreover, it inhibits tumor growth in mice at a low light dose with negligible side effects. PtPAN is the first reported platinum-based photosensitizer that is unreactive to DNA in the dark but highly cytotoxic upon near-infrared (NIR) irradiation for oxygen-independent photodynamic therapy. Owing to its two-photon excitation property (lambda = 825 nm), PtPAN may be suitable for the treatment of deep solid tumors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available